There is no obligation for EIQ or any company to list its competitors on its FDA approval, nor is there any reason to assume competitors are waiting for EIQ to lead the way. This is a marathon, not a sprint. EIQ’s focus should remain on its own strengths, progress, and ability to meet customer needs, rather than being distracted by what competitors are doing. Competitors do not issue approvals or contribute revenue; the company’s priority should be its own growth, innovation, and execution.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
-0.015(6.67%) |
Mkt cap ! $135.4M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 20.5¢ | $1.084M | 5.068M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 99174 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 38542 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| EIQ (ASX) Chart |